Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorJuan Carlos Cardet

About this trial

This study is testing a new way to help adults with asthma get follow up care after an emergency room (ER) visit for an asthma attack. Many people who come to the ER for asthma never see an asthma specialist afterward, even though specialists can offer treatments such as advanced inhalers or biologic medicines that may prevent future attacks.

The study will compare two approaches. One group will receive a telehealth appointment with an asthma specialist that is scheduled for them before they leave the ER. The other group will receive the usual care, which typically includes a standard referral but no scheduled appointment. All participants will be offered a prescription for standard controller medication at discharge.

The main question the study aims to answer is whether arranging a telehealth visit directly from the ER increases the number of patients who complete a follow up appointment with an asthma specialist within three months. The study will also look at whether this approach improves asthma control, reduces repeat ER visits, and helps patients better understand and use their asthma medications.

This research may help identify a practical way to improve access to asthma specialists and reduce the burden of asthma for patients who frequently rely on emergency care.

Eligibility criteria

Qualifiers

Age ≥18 years

Asthma diagnosis ≥1 year

Seen in ER for asthma exacerbation

Persistent asthma on controller therapy

Disqualifiers

Patients who have seen an asthma specialist (allergist or pulmonologist) for asthma in the past 2 years

Diagnosis of other pulmonary diseases (e.g., COPD, interstitial lung disease, etc.)

Trial design

Treatments tested in this trial

  • ER-Initiated Telehealth Referral

Treatment groups

40 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Juan Carlos Cardet

Lead sponsor

University of South Florida

Sponsor institution

Tampa General Hospital

Collaborator

University of South Florida

Collaborator

Sanofi

Collaborator